(Q44291805)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

title

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

author name string

Claire M Shipman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Ben Van Camp

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Karin Vanderkerken

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

language of work or name

English

0 references

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

818-824

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

issue

3 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

17 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

The assessment of vertebral deformity: a method for use in population studies and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Quantitative histology of myeloma-induced bone changes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

The 5TMM series: a useful in vivo mouse model of human multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Evidence for the secretion of an osteoclast stimulating factor in myeloma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Bone-Resorbing Activity in Supernatants from Lymphoid Cell Lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11125

7 January 2021

Identifiers

DOI

10.1002/CNCR.11125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548581%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference